Combinations of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8450272
APP PUB NO 20090029910A1
SERIAL NO

12162715

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a combination of two or more Somatostatin (SRIF) peptidomimetics (also referred to as Somatostatin- or SRIF-analogs) which have different selectivity for the five human somatostatin receptor subtypes, the use of such combination in the treatment of a disease mediated by activation of somatostatin receptors, and to pharmaceutical compositions comprising such a combination.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
NOVARTIS AG4056 BASEL
NOVARTIS PHARMA GMBHBRUNNER STRASSE 59 VIENNA 1230

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Schmid, Herbert Neuenburg, DE 33 337

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Nov 28, 2024
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00